CoChat

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms

Open access

Published version of a preprint

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Serum tryptase is a biomarker used to aid in the identification of certain myeloid neoplasms, most notably systemic mastocytosis, where basal serum tryptase (BST) levels >20 ng/mL are a minor criterion for diagnosis. Although clonal myeloid neoplasms are rare, the common cause for elevated BST levels is the genetic trait hereditary α-tryptasemia (HαT) caused by increased germline TPSAB1 copy number. To date, the precise structural variation and mechanism(s) underlying elevated BST in HαT and the general clinical utility of tryptase genotyping, remain undefined. Through cloning, long-read sequencing, and assembling of the human tryptase locus from an individual with HαT, and validating our findings in vitro and in silico, we demonstrate that BST elevations arise from overexpression of replicated TPSAB1 loci encoding canonical α-tryptase protein owing to coinheritance of a linked overactive promoter element. Modeling BST levels based on TPSAB1 replication number, we generate new individualized clinical reference values for the upper limit of normal. Using this personalized laboratory medicine approach, we demonstrate the clinical utility of tryptase genotyping, finding that in the absence of HαT, BST levels >11.4 ng/mL frequently identify indolent clonal mast cell disease. Moreover, substantial BST elevations (eg, >100 ng/mL), which would ordinarily prompt bone marrow biopsy, can result from TPSAB1 replications alone and thus be within normal limits for certain individuals with HαT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2022007936

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Visual Abstract
Graphical abstract Visual AbstractCC BY-NC-ND · PubMed Central
Figure 1. TPSAB1 duplications occur at 16p13.3 and are linked to an expanded promoter associated with αDUP-tryptase overexpression. (A) Location and orientation of the 15-kb tandem duplication of TPSAB1. (B) Alignment of αDUP-, αWT-, and β-tryptases with unique 5′ variants and size of promoter repeat regions indicated; (C) repeat motif within promoter regions. Relative total α- to β-tryptase gene expression (D) and αDUP-tryptase relative to αWT-tryptase gene expression (E) in ex vivo basophils and cultured primary mast cells. ∗P < .05; ∗∗P < .005.
Figure 1. TPSAB1 duplications occur at 16p13.3 and are linked to an expanded promoter associated with αDUP-tryptase overexpression. (A) Location and orientation of the 15-kb tandem duplication of TPSAB1. (B) Alignment of αDUP-, αWT-, and β-tryptases with unique 5′ variants and size of promoter repeat regions indicated; (C) repeat motif within promoter regions. Relative total α- to β-tryptase gene expression (D) and αDUP-tryptase relative to αWT-tryptase gene expression (E) in ex vivo basophils and cultured primary mast cells. ∗P < .05; ∗∗P < .005.CC BY-NC-ND · PubMed Central
Figure 2. The expanded promoter at duplicated TPSAB1 is conserved and has increased basal activity. (A) Normalized fluorescent reporter activity in unstimulated MonoMac-6 cells transfected with promoters cloned from endogenous (αWT) or replicated (αDUP) TPSAB1 loci. (B) BST from individuals grouped by TPSAB1 replication number. (C-D) Relative allelic frequency (C) and ratios (D) of αWT-tryptase (y-axis) and αDUP-tryptase (x-axis) associated 5′ variants determined by ddPCR. Dashed lines indicate predicted αWT:αDUP ratios by genotype. ∗P < .05.
Figure 2. The expanded promoter at duplicated TPSAB1 is conserved and has increased basal activity. (A) Normalized fluorescent reporter activity in unstimulated MonoMac-6 cells transfected with promoters cloned from endogenous (αWT) or replicated (αDUP) TPSAB1 loci. (B) BST from individuals grouped by TPSAB1 replication number. (C-D) Relative allelic frequency (C) and ratios (D) of αWT-tryptase (y-axis) and αDUP-tryptase (x-axis) associated 5′ variants determined by ddPCR. Dashed lines indicate predicted αWT:αDUP ratios by genotype. ∗P < .05.CC BY-NC-ND · PubMed Central
Figure 3. Modeling serum tryptase levels based on genotype improves clinical utility. (A) Normalized (left) and total (right) read counts for reads aligning exactly to the 39-bp consensus sequences that identify β-, αWT-, and αDUP-tryptase. (B) BST levels among individuals with conserved 4n tryptase copy number (combined from TPSAB1 and TPSB2). (C) Regression analysis of relative expression levels of αDUP-tryptase (y-axis) and αWT-tryptase (x-axis) transcripts. (D) Prediction intervals for BST levels based on TPSAB1 replication number. (E) Prevalence of HαT, clonal MCD, and those without either among individuals referred with BST levels above the predicted upper limit of normal (>11.4 ng/mL). ∗P < .01; ∗∗P < .005; ∗∗∗P < .0001.
Figure 3. Modeling serum tryptase levels based on genotype improves clinical utility. (A) Normalized (left) and total (right) read counts for reads aligning exactly to the 39-bp consensus sequences that identify β-, αWT-, and αDUP-tryptase. (B) BST levels among individuals with conserved 4n tryptase copy number (combined from TPSAB1 and TPSB2). (C) Regression analysis of relative expression levels of αDUP-tryptase (y-axis) and αWT-tryptase (x-axis) transcripts. (D) Prediction intervals for BST levels based on TPSAB1 replication number. (E) Prevalence of HαT, clonal MCD, and those without either among individuals referred with BST levels above the predicted upper limit of normal (>11.4 ng/mL). ∗P < .01; ∗∗P < .005; ∗∗∗P < .0001.CC BY-NC-ND · PubMed Central
Figure 4. Tryptase genotyping in the evaluation of patients with elevated BST. Stepwise approach to a patient workup based on BST level and tryptase genotype using the BST CALCULATER. Myeloid neoplasms often exist in the absence of elevated BST; this algorithm is intended only to aid in the correct interpretation of elevated BST when other indications for workup are absent/nonspecific. AD, autosomal dominant; NGS, next-generation sequencing; ULN, upper limit of normal. ∗At the time of this publication, this is the only Clinical Laboratory Improvement Amendments/College of American Pathologists–certified laboratory performing tryptase genotyping. †Only α-tryptase–encoding TPSAB1 replications are associated with elevated BST and require correction. ‡BST elevation is not a requirement for any clonal neoplasm, and evaluation should be guided by clinical presentation and findings. §Allele-specific PCR or ddPCR should be used because of low allelic frequency.
Figure 4. Tryptase genotyping in the evaluation of patients with elevated BST. Stepwise approach to a patient workup based on BST level and tryptase genotype using the BST CALCULATER. Myeloid neoplasms often exist in the absence of elevated BST; this algorithm is intended only to aid in the correct interpretation of elevated BST when other indications for workup are absent/nonspecific. AD, autosomal dominant; NGS, next-generation sequencing; ULN, upper limit of normal. ∗At the time of this publication, this is the only Clinical Laboratory Improvement Amendments/College of American Pathologists–certified laboratory performing tryptase genotyping. †Only α-tryptase–encoding TPSAB1 replications are associated with elevated BST and require correction. ‡BST elevation is not a requirement for any clonal neoplasm, and evaluation should be guided by clinical presentation and findings. §Allele-specific PCR or ddPCR should be used because of low allelic frequency.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. 1989, Molecular Cloning: A Laboratory Manual

Cited by

See all 62

Metadata

Authors
Chovanec, J., Tunc, I., Hughes, J., Halstead, J., Mateja, A., Liu, Y., O’Connell, M. P., Kim, J., Park, Y. H., Wang, Q., Le, Q., Pirooznia, M., Trivedi, N. N., Bai, Y., Yin, Y., Hsu, A. P., McElwee, J., Lassiter, S., Nelson, C., Bandoh, J., DiMaggio, T., Šelb, J., Rijavec, M., Carter, M. C., Komarow, H. D., Sabato, V., Steinberg, J., Hafer, K. M., Feuille, E., Hourigan, C. S., Lack, J., Khoury, P., Maric, I., Zanotti, R., Bonadonna, P., Schwartz, L. B., Milner, J. D., Glover, S. C., Ebo, D. G., Korošec, P., Caughey, G. H., Brittain, E. H., Busby, B., Metcalfe, D. D., & Lyons, J. J.
Affiliations
  • National Institutes of Health (US)
  • Foundation Medicine (United States) (US)
  • Birmingham Women’s and Children’s NHS Foundation Trust (GB)
  • Frederick National Laboratory for Cancer Research (US)
  • 1Translational Allergic Immunopathology Unit, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD
  • Virginia Commonwealth University (US)
  • San Francisco VA Medical Center (US)
  • 12Nimbus Therapeutics, Cambridge, MA
  • University Clinic of Pulmonary and Allergic Diseases Golnik (SI)
  • University of Antwerp (BE)
  • Medical College of Wisconsin (US)
  • Stanford Medicine (US)
  • Cornell University (US)
  • 23Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD
  • University of Verona (IT)
  • Azienda Ospedaliera Universitaria Integrata Verona (IT)
  • Columbia University (US)
  • University of Mississippi Medical Center (US)
Corresponding author
Lyons, Jonathan J.
Venue
Blood Advances
Published
2023-04-28
Volume
7
Issue
9
Pages
1796-1810
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W4297520278
Cited by
62
References
36
Citations by year
2026: 11 · 2025: 24 · 2024: 13 · 2023: 11
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • medRxiv (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health and Human Services (HHSN261201500003I)
  • Fonds Wetenschappelijk Onderzoek (1804518N, 1800614N, FWO: 1800614N)
  • Vlaamse regering
  • National Institutes of Health (75N910D00024, HHSN261201500003I)
  • National Heart, Lung, and Blood Institute
  • National Cancer Institute (75N910D00024, HHSN261201500003I, HHSN261201500003C)
  • National Institute of Allergy and Infectious Diseases (HHSN261201500003I, 75N910D00024)
  • National Institute of Dental and Craniofacial Research (R21DE028378)
  • U.S. National Library of Medicine
  • NHLBI Division of Intramural Research
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
serum tryptase, hereditary alpha-tryptasemia, upper limit of normal, systemic mastocytosis, myeloid neoplasms
MeSH terms
Mast Cell Activation Syndrome, Humans, Mast Cells, Mastocytosis, Myeloproliferative Disorders, Reference Values, Unnecessary Procedures, Tryptases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. https://app.cochat.ai/papers/10.1182/bloodadvances.2022007936
The paper
Chovanec, J., Tunc, I., Hughes, J., Halstead, J., Mateja, A., Liu, Y., O’Connell, M. P., Kim, J., Park, Y. H., Wang, Q., Le, Q., Pirooznia, M., Trivedi, N. N., Bai, Y., Yin, Y., Hsu, A. P., McElwee, J., Lassiter, S., Nelson, C., . . . Lyons, J. J. (2023). Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Advances. https://doi.org/10.1182/bloodadvances.2022007936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.